| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.95 | 30.9% | 11.4% |
| Total Income | 1.95 | 30.9% | 11.4% |
| Expenditure | 19.70 | 9.9% | 1.6% |
| PBT | — | ||
| Net Profit | -3.60 | 85.5% | 82.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.01 | 85.7% |
Ocugen Reports Q3 2026 Financial Results and Business Updates
04 Nov 2026 · 4 Nov, 7:01 pm
Summary
Ocugen, Inc. reported its third quarter 2026 financial results and provided a business update. As of September 30, 2026, the company held $84.6 million in cash, cash equivalents, restricted cash, and short-term investments, with an anticipated runway into 2028. Total operating expenses for the quarter were $19.7 million. The company reported a net loss per common share of $(0.01) for the third quarter of 2026, an improvement from $(0.07) in the prior year period. Key business updates include provisional approval for OCU400 in The Bahamas, a MENA license agreement for OCU400, and the initiation of the Phase 3 ArMaDa3 trial for OCU410.
Key Highlights
- 1
Ocugen reported cash, cash equivalents, restricted cash, and short-term investments totaling $84.6 million as of September 30, 2026, with an expected runway into 2028.
- 2
The company had 339.3 million shares of common stock outstanding as of September 30, 2026.
- 3
Total operating expenses for the three months ended September 30, 2026, were $19.7 million, including $12.5 million for research and development and $7.2 million for general and administrative expenses.
- 4
Ocugen reported a net loss per common share of $(0.01) for the three months ended September 30, 2026, compared to a net loss per common share of $(0.07) for the three months ended September 30, 2025.
- 5
The company received Provisional Approval and Priority Designation for OCU400 in The Bahamas and executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical.
- 6
Ocugen initiated dosing in the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) and expects topline data from the OCU400 Phase 3 liMeliGhT trial in the first quarter of 2027.
- 7
Topline data from the Phase 2/3 pivotal confirmatory trial of OCU410ST for Stargardt disease are anticipated in the second quarter of 2027.
Management Comments
Dr. Shankar Musunuri
With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide. As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.
Informational and educational content only. Not investment advice.